
Mike Doustdar
PersonHeard in 14 episodes across 2 shows since Sep 2025
Maziar "Mike" Doustdar is a business executive who has appeared as a guest on the podcast 'Stock Movers'. He is known for his professional contributions in the corporate sector, including discussions on major market and industry developments.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 3 |
| Dec 2025 | 1 |
| Jan 2026 | 3 |
| Feb 2026 | 1 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 1 |
| Jul 2026 | 0 |
| Aug 2026 | 1 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
Email alert
Email me when Mike Doustdar comes up on a podcast
One email a week at most, with the new episodes that mention Mike Doustdar. Free, no account needed, unsubscribe in one click.
What Mike Doustdar has said on podcasts
17 statements
Novo Nordisk’s pill launch is the best pharmaceutical product launch ever.
“this makes this launch the best product launch in the history of pharmaceuticals.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 12:48
Novo Nordisk improved guidance and exceeded consensus expectations.
“we improved guidance, actually, and beat the consensus quite a bit.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 13:24
Novo Nordisk substantially reduced Ozempic and Wegovy prices.
“we reduced the prices of Ozempic and Vigovie tremendously.”
Open the episode · Mad Money w/ Jim Cramer 8/12/26Listen at 14:03
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
14 episodes featuring Mike Doustdar, newest first
- Aug 12, 2026
Cramer weighs durable growth against market noiseMad Money w/ Jim CramerAug 12, 2026Guest - Jun 16, 2026
SpaceX subsidiary merges with Cursor in sixty billion dollar AI dealStock MoversJun 16, 2026Guest - Feb 5, 2026
Cramer warns rotation punishes high-flying stocksMad Money w/ Jim CramerFeb 5, 2026Guest - Jan 23, 2026
Cramer weighs stock selection against broad market gainsMad Money w/ Jim CramerJan 23, 2026 - Jan 17, 2026
Cramer links market volatility to business quality and chip demandMad Money w/ Jim CramerJan 17, 2026 - Jan 13, 2026
Healthcare CEOs pitch obesity drugs and device breakthroughsMad Money w/ Jim CramerJan 13, 2026Guest